Australian Broker Call
Produced and copyrighted by 
at www.fnarena.com
April 09, 2018
Access Broker Call Report Archives here
COMPANIES DISCUSSED IN THIS ISSUE
Click on symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
THIS REPORT WILL BE UPDATED SHORTLY
Last Updated: 10:23 AM
Your daily news report on the latest recommendation, valuation, forecast and opinion changes.
This report includes concise but limited reviews of research recently published by Stockbrokers, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end.
For more info about the different terms used by stockbrokers, as well as the different methodologies behind similar sounding ratings, download our guide HERE
ANN ANSELL LIMITED
Commercial Services & Supplies
More Research Tools In Stock Analysis - click HERE
Overnight Price: $25.34
Ord Minnett rates ANN as Accumulate (2) -
Ord Minnett undertakes its quarterly currency model update with the main change being the strengthening of the euro and pound sterling against the Australian dollar and US dollar.
The broker also revises the spot AUD/USD rate to 0.77 for valuing companies reporting in US dollars.
Accumulate retained. Target is raised to $26.80 from $26.50.
This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.
Target price is $26.80 Current Price is $25.34 Difference: $1.46
If ANN meets the Ord Minnett target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $25.29, suggesting downside of -0.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Ord Minnett forecasts a full year FY18 dividend of 59.44 cents and EPS of 184.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 138.3, implying annual growth of N/A. Current consensus DPS estimate is 57.3, implying a prospective dividend yield of 2.3%. Current consensus EPS estimate suggests the PER is 18.3. |
Forecast for FY19:
Ord Minnett forecasts a full year FY19 dividend of 62.02 cents and EPS of 203.26 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 155.3, implying annual growth of 12.3%. Current consensus DPS estimate is 60.6, implying a prospective dividend yield of 2.4%. Current consensus EPS estimate suggests the PER is 16.3. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CSL CSL LIMITED
Pharmaceuticals & Biotech/Lifesciences
More Research Tools In Stock Analysis - click HERE
Overnight Price: $157.99
Ord Minnett rates CSL as Accumulate (2) -
Ord Minnett undertakes its quarterly currency model update with the main change being the strengthening of the euro and pound sterling against the Australian dollar and US dollar.
The broker also revises the spot AUD/USD rate to 0.77 for valuing companies reporting in US dollars. Accumulate rating maintained. Target is raised to $171 from $166.
This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.
Target price is $171.00 Current Price is $157.99 Difference: $13.01
If CSL meets the Ord Minnett target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $167.14, suggesting upside of 5.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Ord Minnett forecasts a full year FY18 dividend of 208.04 cents and EPS of 477.06 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 467.9, implying annual growth of N/A. Current consensus DPS estimate is 202.3, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 33.8. |
Forecast for FY19:
Ord Minnett forecasts a full year FY19 dividend of 239.05 cents and EPS of 547.62 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 532.6, implying annual growth of 13.8%. Current consensus DPS estimate is 227.6, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 29.7. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates CSL as Buy (1) -
Canada has announced changes to the sourcing of immunoglobulin from the various commercial operators. For CSL, this will result in a decline in the percentage contribution to total purchased IG to 10% in FY19 from around 26% in FY18.
UBS calculates a CAD$44m decline in IG revenue for CSL in FY19. However, this lost revenue represents just 1% of sales globally for the group. Buy rating and $175 target maintained.
Target price is $175.00 Current Price is $157.99 Difference: $17.01
If CSL meets the UBS target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $167.14, suggesting upside of 5.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
UBS forecasts a full year FY18 dividend of 197.70 cents and EPS of 469.05 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 467.9, implying annual growth of N/A. Current consensus DPS estimate is 202.3, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 33.8. |
Forecast for FY19:
UBS forecasts a full year FY19 dividend of 215.82 cents and EPS of 537.61 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 532.6, implying annual growth of 13.8%. Current consensus DPS estimate is 227.6, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 29.7. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CWY CLEANAWAY WASTE MANAGEMENT LIMITED
Industrial Sector Contractors & Engineers
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.43
Morgans rates CWY as Add (1) -
Morgans has included Cleanaway in its high conviction list. A recent presentation to the broker's adviser network has reinforced confidence in a positive outlook.
The company's competitive advantages include its market share leadership in collection volumes, diversity of operations, customer base and waste management facilities.
Morgans expects relatively defensive and solid earnings growth, at around 7% for EBITDA in FY18. Earnings per share growth is more difficult to forecast because of the Tox Free acquisition. The broker reiterates an Add rating and $1.68 target.
Target price is $1.68 Current Price is $1.43 Difference: $0.25
If CWY meets the Morgans target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $1.63, suggesting upside of 13.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Morgans forecasts a full year FY18 dividend of 2.10 cents and EPS of 5.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 4.8, implying annual growth of 4.3%. Current consensus DPS estimate is 2.1, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 29.8. |
Forecast for FY19:
Morgans forecasts a full year FY19 dividend of 3.40 cents and EPS of 6.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 6.6, implying annual growth of 37.5%. Current consensus DPS estimate is 2.7, implying a prospective dividend yield of 1.9%. Current consensus EPS estimate suggests the PER is 21.7. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $4.99
UBS rates IGO as Neutral (3) -
UBS observes earnings will skew further towards Nova and nickel, and away from Tropicana and gold, as Nova approaches nameplate production in the current half-year.
While Tropicana is a strongly performing asset, delivering lengthening mine life and lifting margins, the company's interest at 30% makes it a relatively small contributor. In addition, with lifting expectations for nickel, the relevance may only decline further.
Hence, UBS suggests, in a scenario where Tropicana was divested, the market could respond favourably to the increased leverage to Nova and nickel/battery related commodities. Neutral rating maintained. Target rises to $5.10 from $4.40.
Target price is $5.10 Current Price is $4.99 Difference: $0.11
If IGO meets the UBS target it will return approximately 2% (excluding dividends, fees and charges).
Current consensus price target is $4.67, suggesting downside of -6.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
UBS forecasts a full year FY18 dividend of 4.00 cents and EPS of 11.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.8, implying annual growth of 473.4%. Current consensus DPS estimate is 6.0, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 29.7. |
Forecast for FY19:
UBS forecasts a full year FY19 dividend of 9.00 cents and EPS of 32.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 37.1, implying annual growth of 120.8%. Current consensus DPS estimate is 11.0, implying a prospective dividend yield of 2.2%. Current consensus EPS estimate suggests the PER is 13.5. |
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.55
Morgan Stanley rates IPL as Equal-weight (3) -
Morgan Stanley makes forecast adjustments to reflect the impact of higher fertiliser prices and adverse weather. The broker also adjusts the potential benefits associated with US tax rates.
Valuation is unchanged. FY18 earnings forecasts are lowered by -5%, while beyond FY18 forecasts are largely unchanged.
The broker retains an Equal-weight rating and Cautious industry view. The target is $3.90.
Target price is $3.90 Current Price is $3.55 Difference: $0.35
If IPL meets the Morgan Stanley target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $4.04, suggesting upside of 13.9% (ex-dividends)
The company's fiscal year ends in September.
Forecast for FY18:
Morgan Stanley forecasts a full year FY18 dividend of 13.00 cents and EPS of 22.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.1, implying annual growth of 16.9%. Current consensus DPS estimate is 11.5, implying a prospective dividend yield of 3.2%. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY19:
Morgan Stanley forecasts a full year FY19 dividend of 14.00 cents and EPS of 23.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.5, implying annual growth of 6.3%. Current consensus DPS estimate is 12.2, implying a prospective dividend yield of 3.4%. Current consensus EPS estimate suggests the PER is 15.1. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
JHG JANUS HENDERSON GROUP PLC.
Wealth Management & Investments
More Research Tools In Stock Analysis - click HERE
Overnight Price: $41.38
UBS rates JHG as Buy (1) -
With negative equity markets and active asset management still under pressure, particularly in the US, UBS suspects flows were soft in the March quarter.
Management commentary around institutional trends and performance has been upbeat, although the broker notes Morningstar retail fund data indicates net outflows in January/February.
The broker retains a Buy rating. Target is reduced to US$41.15 from US$43.40.
Current Price is $41.38. Target price not assessed.
Current consensus price target is $54.24, suggesting upside of 31.1% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY18:
UBS forecasts a full year FY18 dividend of 182.97 cents and EPS of 366.07 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 366.5, implying annual growth of N/A. Current consensus DPS estimate is 181.1, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 11.3. |
Forecast for FY19:
UBS forecasts a full year FY19 dividend of 230.78 cents and EPS of 384.68 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 397.4, implying annual growth of 8.4%. Current consensus DPS estimate is 210.7, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 10.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MFG MAGELLAN FINANCIAL GROUP LIMITED
Wealth Management & Investments
More Research Tools In Stock Analysis - click HERE
Overnight Price: $23.15
UBS rates MFG as Buy (1) -
With negative equity markets and active asset management still under pressure, particularly in the US, UBS suspects flows were soft in the March quarter.
Still, Morningstar data signals Magellan enjoyed strong institutional flows despite a weak close at the December quarter.
Buy rating maintained. Target is reduced to $28.00 from $29.30.
Target price is $28.00 Current Price is $23.15 Difference: $4.85
If MFG meets the UBS target it will return approximately 21% (excluding dividends, fees and charges).
Current consensus price target is $28.68, suggesting upside of 23.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
UBS forecasts a full year FY18 dividend of 94.60 cents and EPS of 100.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 129.4, implying annual growth of 10.7%. Current consensus DPS estimate is 98.4, implying a prospective dividend yield of 4.3%. Current consensus EPS estimate suggests the PER is 17.9. |
Forecast for FY19:
UBS forecasts a full year FY19 dividend of 112.50 cents and EPS of 152.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 155.1, implying annual growth of 19.9%. Current consensus DPS estimate is 115.0, implying a prospective dividend yield of 5.0%. Current consensus EPS estimate suggests the PER is 14.9. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $12.24
Credit Suisse rates RMD as Neutral (3) -
Credit Suisse has reviewed the French CPAP market and upgrades earnings estimates by around 1.5% because of stronger growth in masks.
The broker remains upbeat of the potential for robust growth in the rest of the world and US masks sales. However, valuation appears full and the broker retains a Neutral rating. Target is raised to $11.95 from $11.30.
Target price is $11.95 Current Price is $12.24 Difference: minus $0.29 (current price is over target).
If RMD meets the Credit Suisse target it will return approximately minus 2% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $12.33, suggesting upside of 0.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Credit Suisse forecasts a full year FY18 dividend of 18.48 cents and EPS of 41.89 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 100.4, implying annual growth of N/A. Current consensus DPS estimate is 18.5, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 12.2. |
Forecast for FY19:
Credit Suisse forecasts a full year FY19 dividend of 20.03 cents and EPS of 42.96 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 104.5, implying annual growth of 4.1%. Current consensus DPS estimate is 19.6, implying a prospective dividend yield of 1.6%. Current consensus EPS estimate suggests the PER is 11.7. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates RMD as Hold (3) -
Ord Minnett undertakes its quarterly currency model update with the main change being the strengthening of the euro and pound sterling against the Australian dollar and US dollar.
The broker also revises the spot AUD/USD rate to 0.77 for valuing companies reporting in US dollars. Hold rating maintained. Target is raised to $12.20 from $11.25.
This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.
Target price is $12.20 Current Price is $12.24 Difference: minus $0.04 (current price is over target).
If RMD meets the Ord Minnett target it will return approximately minus 0% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $12.33, suggesting upside of 0.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Ord Minnett forecasts a full year FY18 EPS of 444.24 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 100.4, implying annual growth of N/A. Current consensus DPS estimate is 18.5, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 12.2. |
Forecast for FY19:
Ord Minnett forecasts a full year FY19 EPS of 458.07 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 104.5, implying annual growth of 4.1%. Current consensus DPS estimate is 19.6, implying a prospective dividend yield of 1.6%. Current consensus EPS estimate suggests the PER is 11.7. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $4.10
Credit Suisse rates SBM as Neutral (3) -
Preliminary March quarter production of 85,900 ounces has been announced while the company has increased FY18 guidance to 375-392,000 ounces.
The upgrade was driven by an improved outlook at Simberi. The March quarter was soft at Gwalia but a stronger fourth quarter is envisaged.
Neutral. Target is $3.85.
Target price is $3.85 Current Price is $4.10 Difference: minus $0.25 (current price is over target).
If SBM meets the Credit Suisse target it will return approximately minus 6% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $3.99, suggesting downside of -2.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Credit Suisse forecasts a full year FY18 dividend of 9.08 cents and EPS of 35.87 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 37.1, implying annual growth of 17.0%. Current consensus DPS estimate is 9.2, implying a prospective dividend yield of 2.2%. Current consensus EPS estimate suggests the PER is 11.1. |
Forecast for FY19:
Credit Suisse forecasts a full year FY19 dividend of 9.80 cents and EPS of 32.68 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 33.5, implying annual growth of -9.7%. Current consensus DPS estimate is 10.2, implying a prospective dividend yield of 2.5%. Current consensus EPS estimate suggests the PER is 12.2. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates SBM as Outperform (1) -
Preliminary March quarter production was softer than Macquarie expected, although cash generation was greater than forecast. The company has lifted FY18 production guidance to 375-392,000 ounces on the back of a stronger fourth quarter outlook.
Macquarie lowers its FY18 production assumptions by -2% after incorporating the result. Mill throughput at Gwalia was the driver of lower production, partially offset by strong milled grade. Outperform rating and $4.70 target maintained.
Target price is $4.70 Current Price is $4.10 Difference: $0.6
If SBM meets the Macquarie target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $3.99, suggesting downside of -2.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Macquarie forecasts a full year FY18 dividend of 9.00 cents and EPS of 37.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 37.1, implying annual growth of 17.0%. Current consensus DPS estimate is 9.2, implying a prospective dividend yield of 2.2%. Current consensus EPS estimate suggests the PER is 11.1. |
Forecast for FY19:
Macquarie forecasts a full year FY19 dividend of 9.00 cents and EPS of 33.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 33.5, implying annual growth of -9.7%. Current consensus DPS estimate is 10.2, implying a prospective dividend yield of 2.5%. Current consensus EPS estimate suggests the PER is 12.2. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SLK SEALINK TRAVEL GROUP LIMITED
Travel, Leisure & Tourism
More Research Tools In Stock Analysis - click HERE
Overnight Price: $3.88
Ord Minnett rates SLK as Buy (1) -
Ord Minnett has undertaken a detailed review of the first half results and industry data. The broker believes the Kangaroo Island business has a sustainable competitive advantage and current threats have a limited impact on near-term earnings. Closer examination of the Fraser Island acquisition suggests the investment case appears compelling.
Meanwhile, the CCC segment has been affected by an underperforming Western Australian business and start-up losses, although the medium-term travel industry dynamics appear sound for both Sydney and Perth. Ord Minnett suspects Gladstone earnings are likely to have found a base and other businesses in the Queensland/NT division seem well-positioned.
Buy rating maintained. Target is raised to $4.69 from $4.59.
Target price is $4.69 Current Price is $3.88 Difference: $0.81
If SLK meets the Ord Minnett target it will return approximately 21% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY18:
Ord Minnett forecasts a full year FY18 dividend of 12.20 cents and EPS of 22.20 cents. |
Forecast for FY19:
Ord Minnett forecasts a full year FY19 dividend of 14.20 cents and EPS of 26.80 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SUL SUPER RETAIL GROUP LIMITED
Automobiles & Components
More Research Tools In Stock Analysis - click HERE
Overnight Price: $6.84
Morgan Stanley rates SUL as Equal-weight (3) -
Morgan Stanley updates forecasts following the Macpac acquisition and the update on Rays. While cautious about the Macpac acquisition the broker retains an Equal-weight rating.
The broker continues to have concerns around capital allocation but suspects valuation will remain cheap, particularly as the balance sheet now looks stretched. Target is $7. Industry View: Cautious.
Target price is $7.00 Current Price is $6.84 Difference: $0.16
If SUL meets the Morgan Stanley target it will return approximately 2% (excluding dividends, fees and charges).
Current consensus price target is $8.18, suggesting upside of 19.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Morgan Stanley forecasts a full year FY18 dividend of 47.00 cents and EPS of 70.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 70.0, implying annual growth of 35.7%. Current consensus DPS estimate is 47.2, implying a prospective dividend yield of 6.9%. Current consensus EPS estimate suggests the PER is 9.8. |
Forecast for FY19:
Morgan Stanley forecasts a full year FY19 dividend of 55.00 cents and EPS of 82.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 77.5, implying annual growth of 10.7%. Current consensus DPS estimate is 52.0, implying a prospective dividend yield of 7.6%. Current consensus EPS estimate suggests the PER is 8.8. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $4.22
Citi rates TAH as Buy (1) -
Citi analysts have further sliced their EPS growth expectations, leaving very little on the table (0.3% only) for Tabcorp's wagering and media division. The analysts do note their updated forecasts are not materially different from market consensus.
Obviously, everybody is expecting growth in lotteries will provide for compensation, including Citi. Expectations are supported by a favourable YTD jackpot run alongside benefits from a pending price and odds increase for Powerball.
Buy rating retained with the analysts arguing the current share price reflects nil value for the wagering assets. Price target $5.95.
Target price is $5.95 Current Price is $4.22 Difference: $1.73
If TAH meets the Citi target it will return approximately 41% (excluding dividends, fees and charges).
Current consensus price target is $5.27, suggesting upside of 24.9% (ex-dividends)
Forecast for FY18:
Citi forecasts a full year FY18 dividend of 20.00 cents and EPS of 17.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.2, implying annual growth of N/A. Current consensus DPS estimate is 20.5, implying a prospective dividend yield of 4.9%. Current consensus EPS estimate suggests the PER is 26.0. |
Forecast for FY19:
Citi forecasts a full year FY19 dividend of 22.00 cents and EPS of 20.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 21.5, implying annual growth of 32.7%. Current consensus DPS estimate is 22.1, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 19.6. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Summaries
| ANN | ANSELL | Accumulate - Ord Minnett | Overnight Price $25.34 |
| CSL | CSL | Accumulate - Ord Minnett | Overnight Price $157.99 |
| Buy - UBS | Overnight Price $157.99 | ||
| CWY | CLEANAWAY WASTE MANAGEMENT | Add - Morgans | Overnight Price $1.43 |
| IGO | INDEPENDENCE GROUP | Neutral - UBS | Overnight Price $4.99 |
| IPL | INCITEC PIVOT | Equal-weight - Morgan Stanley | Overnight Price $3.55 |
| JHG | JANUS HENDERSON GROUP | Buy - UBS | Overnight Price $41.38 |
| MFG | MAGELLAN FINANCIAL GROUP | Buy - UBS | Overnight Price $23.15 |
| RMD | RESMED | Neutral - Credit Suisse | Overnight Price $12.24 |
| Hold - Ord Minnett | Overnight Price $12.24 | ||
| SBM | ST BARBARA | Neutral - Credit Suisse | Overnight Price $4.10 |
| Outperform - Macquarie | Overnight Price $4.10 | ||
| SLK | SEALINK TRAVEL | Buy - Ord Minnett | Overnight Price $3.88 |
| SUL | SUPER RETAIL | Equal-weight - Morgan Stanley | Overnight Price $6.84 |
| TAH | TABCORP HOLDINGS | Buy - Citi | Overnight Price $4.22 |
RATING SUMMARY
| Rating | No. Of Recommendations |
| 1. Buy | 7 |
| 2. Accumulate | 2 |
| 3. Hold | 6 |
Monday 09 April 2018
Access Broker Call Report Archives here
Disclaimer:
The content of this information does in no way reflect the opinions of
FNArena, or of its journalists. In fact we don't have any opinion about
the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe
and comment on. By doing so we believe we provide intelligent investors
with a valuable tool that helps them in making up their own minds, reading
market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not
constitute an offer to sell or a solicitation to buy any security or other
financial instrument. FNArena employs very experienced journalists who
base their work on information believed to be reliable and accurate, though
no guarantee is given that the daily report is accurate or complete. Investors
should contact their personal adviser before making any investment decision.
Latest News
| 1 |
The Market In Numbers – 23 Nov 20249:09 AM - Australia |
| 2 |
ASX Winners And Losers Of Today – 22-11-24Nov 22 2024 - Daily Market Reports |
| 3 |
FNArena Corporate Results Monitor – 22-11-2024Nov 22 2024 - Australia |
| 4 |
Next Week At A Glance – 25-29 Nov 2024Nov 22 2024 - Weekly Reports |
| 5 |
Weekly Top Ten News Stories – 22 November 2024Nov 22 2024 - Weekly Reports |